首页> 外文OA文献 >High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases
【2h】

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases

机译:慢性透析患者中​​由于抗促红细胞生成素抗体而在瑞士发生的纯红细胞发育不全的高流行:五例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Pure red-cell aplasia (PRCA) after erythropoietin (Epo) administration due to the appearance of neutralizing anti-Epo antibodies has been reported in over 200 cases between 1998 and 2002. However, large intercountry disparities were observed in the occurrence of this syndrome. Methods. On behalf of the Swiss Society of Nephrology, a survey was conducted in all the dialysis units of Switzerland in order to collect information on the occurrence, diagnostic and evolution data of the cases observed. A questionnaire was send to the nephrologists in charge of each of the 69 dialysis units in January 2003. The clinical and biological data of the suspected cases were analysed and compared with the data provided to health authorities and pharmaceutical companies. Results. A total of five cases were identified as true PRCA with demonstrated positive anti-Epo antibodies. They occurred between November 1998 and February 2002, were all treated by haemodialysis and had received Epo subcutaneously. The median appearance time of refractory anaemia after Epo initiation was 10 months (range: 7-54 months). Two cases had been treated exclusively with epoietin-α, one solely with epoietin-β and the two others with a combination of both. With five cases out of a total of about 2500 dialysis patients and 2300 Epo-treated dialysis patients or an exposure rate to Epo of 9900 dialysis patient-years during a 4.3 year period, this prevalence is among the highest of those reported in European countries. Conclusions. The prevalence of PRCA after Epo administration in dialysis patients appears particularly high in Switzerland. Among the potential explanations, the most plausible are the high percentage of dialysis patients treated with Epo, the almost exclusive subcutaneous administration, the larger market distribution of the epoietin-α brand, the eventual disruption of the cold chain and the setting-up of a systematic national survey
机译:背景。在1998年至2002年之间,已有200多例患者报告了由于出现中和性抗Epo抗体而出现促红细胞生成素(Epo)后发生的纯红细胞发育不良(PRCA)。但是,在该综合征的发生中发现了巨大的国家差异。方法。代表瑞士肾脏病学会,在瑞士所有透析部门进行了一项调查,以收集有关所观察到病例的发生,诊断和演变数据的信息。在2003年1月,向负责69个透析单位的肾脏病学家发送了一份调查问卷。分析了疑似病例的临床和生物学数据,并与提供给卫生当局和制药公司的数据进行了比较。结果。总共有5例被鉴定为真正的PRCA,并显示出抗Epo抗体阳性。它们发生在1998年11月至2002年2月之间,均接受了血液透析治疗,并接受了皮下注射Epo。 Epo启动后难治性贫血的中位出现时间为10个月(范围:7-54个月)。其中有2例仅接受了epoietin-α的治疗,其中1例仅接受了epoietin-β的治疗,另2例则合并了两者。在4.3年内,总共约2500名透析患者和2300名接受Epo治疗的透析患者中​​有5例,或者Epo暴露率为9900透析患者-年,这一患病率是欧洲国家中最高的。结论。在瑞士,Epo注射后透析患者中​​PRCA的患病率特别高。在可能的解释中,最可能的原因是接受Epo治疗的透析患者比例高,几乎是全皮下给药,epoietin-α品牌的市场分布更大,最终冷链中断和建立了Epoietin-α。系统的国家调查

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号